Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01314950
Other study ID # R01AG034946-01A1
Secondary ID R01AG034946-01A1
Status Completed
Phase N/A
First received March 10, 2011
Last updated March 7, 2016
Start date July 2010
Est. completion date December 2015

Study information

Verified date March 2016
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to conduct a two-year randomized, controlled clinical trial to improve functioning among older adults with Alzheimer's disease by comparing a control group receiving best practices primary care with an intervention group receiving best practice primary care plus a home-based occupational therapy intervention.


Description:

The proposed study builds on our findings from a previous clinical trial that demonstrated the effectiveness of collaborative care for older adults with Alzheimer's disease cared for in primary care practices. In the prior trial, we demonstrated that guideline-level medical care resulted in improved quality of care and improved behavioral and psychological symptoms over one year among patients and their caregivers. However, despite finding significant differences among study groups on Neuropsychiatric Inventory scores, we did not find a significant difference between groups in functional decline. Both study groups experienced a significant decline in function over 18 months. The current study proposes to test a home-based intervention specifically designed to slow the rate of functional decline among older adults with Alzheimer's disease.

In addition to building on our past research, the study also builds from recently reported research which demonstrated the short-term efficacy of home-based occupational therapy interventions among older adults with dementia. These trials show that older adults with dementia, including Alzheimer's disease, can both participate in and benefit from occupational therapy-based interventions delivered in the home.

The specific aim of this study is to conduct a two-year, randomized, controlled clinical trial to improve functioning among older adults with Alzheimer's disease by comparing a control group receiving best practices primary care with an intervention group receiving best practice primary care plus a home-based occupational therapy intervention. We will test the primary hypothesis that subjects with Alzheimer's disease in the intervention group will have improved function at two years compared with the best practice primary care control group.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 45 Years and older
Eligibility Patient Inclusion Criteria:

- Currently a patient within Wishard Health Services in Central Indiana

- Diagnosed with possible or probable Alzheimer's Disease

- Age 45 or older

- English speaking

- Hear well enough to answer questions in person or by telephone

- Community-dwelling (includes senior communities, but not skilled nursing facilities)

- Caregiver willing to participate in the study

- Willing to receive home visits

- Lives in Indianapolis metro area and planning to continue care at primary care clinic

Caregiver Inclusion Criteria

- Age 18 or older

- English speaking

- Hear well enough to answer questions in person or by telephone

- Community-dwelling

- Willing to receive home visits

Exclusion Criteria:

- Not a current patient within Wishard Health Services

- Does not speak English

- Currently enrolled in another study

- Non-community dwelling, or residing in a skilled nursing facility

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Home based occupational therapy
An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with "homework" each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs.
Best practices primary care
Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.

Locations

Country Name City State
United States Wishard Health Services Indianapolis Indiana

Sponsors (3)

Lead Sponsor Collaborator
Indiana University National Institute on Aging (NIA), Regenstrief Institute, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Callahan CM, Boustani M, Sachs GA, Hendrie HC. Integrating care for older adults with cognitive impairment. Curr Alzheimer Res. 2009 Aug;6(4):368-74. Review. — View Citation

Callahan CM, Boustani MA, Unverzagt FW, Austrom MG, Damush TM, Perkins AJ, Fultz BA, Hui SL, Counsell SR, Hendrie HC. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006 May 10;295(18):2148-57. — View Citation

Guerriero Austrom M, Damush TM, Hartwell CW, Perkins T, Unverzagt F, Boustani M, Hendrie HC, Callahan CM. Development and implementation of nonpharmacologic protocols for the management of patients with Alzheimer's disease and their families in a multiracial primary care setting. Gerontologist. 2004 Aug;44(4):548-53. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS - ADLI) 24 months No
Secondary Short Physical Performance Battery (SPPB) Includes Side by Side Stand, Semi-Tandem Stand, Tandem Stand, Repeated Chair Stands, and 3 or 4 meter walk Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Tandem Stand, eyes closed Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary One Leg Stand, eyes open Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Mini Mental State Examination Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Word List Learning Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Delayed Word List Recall Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Grip Strength Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Neuropsychiatric Inventory (NPI) Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Alzheimer's Disease Cooperative Studies Resource Use Scale Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary PHQ - 9 Depression Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary GAD - 7 Anxiety Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Comorbid Conditions Baseline, 6 months, 12 months, 18 months, and 24 months No
Secondary Adverse Events Baseline, 6 months, 12 months, 18 months, and 24 months Yes
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02089555 - African American Alzheimer's Progression Markers - CSF and Neuro-Imaging N/A